Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease

American Heart Journal

Volumn 153, Issue 3, 2007, Pages 371-377

  Serebruany, Victor L ^a   Malinin, Alex I ^a   Atar, Dan ^b   Hanley, Dan F ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CD31 ANTIGEN; CLOPIDOGREL; GLYCOPROTEIN IIB; PROTEINASE ACTIVATED RECEPTOR 1;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY STENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TREATMENT RESPONSE; VASCULAR DISEASE;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, CD31; ASPIRIN; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; HUMANS; INTEGRIN BETA3; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET MEMBRANE GLYCOPROTEIN IIB; RISK FACTORS; TICLOPIDINE; VASCULAR DISEASES;

EID: 33847304531     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.12.006     Document Type: Article

References (28)

1. Chen Z.M., Jiang L.X., Chen Y.P., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
2. Steinhubl S.R., Berger P.B., Mann III J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
3. Peters R.J., Mehta S.R., Fox K.A., et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108 (2003) 1682-1687
4. Nguyen T.A., Diodati J.G., and Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45 (2005) 1157-1164
5. Lev E.I., Patel R.T., Maresh K.J., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33
6. Gachet C., and Aleil B. The inter-individual variability of the response to clopidogrel. Arch Mal Coeur Vaiss 98 (2005) 216-225
7. Serebruany V.L., Steinhubl S.R., Berger P.B., et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45 (2005) 246-251
8. Vats H.S., Hocking W.G., and Rezkalla S.H. Suspected clopidogrel resistance in a patient with acute stent thrombosis. Nat Clin Pract Cardiovasc Med 4 (2006) 226-230
9. Duffy B., and Bhatt D.L. Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much?. Am J Cardiovasc Drugs 5 (2005) 307-318
10. Kapetanakis E.I., Medlam D.A., Petro K.R., et al. Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae?. Circulation 113 (2006) 1667-1674
11. von Heymann C., Redlich U., Moritz M., et al. Aspirin and clopidogrel taken until 2 days prior to coronary artery bypass graft surgery is associated with increased postoperative drainage loss. Thorac Cardiovasc Surg 53 (2005) 341-345
12. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 47 (2006) 1-121
13. Serebruany V.L., Miller M., Pokov A.N., et al. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 Inhibition by Statins [PARIS] study). Am J Cardiol 97 (2006) 1332-1336
14. Serebruany V.L., Malinin A.I., Ziai W., et al. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment Of Stroke (PLUTO-Stroke) trial. Stroke 36 (2005) 2289-2292
15. Serebruany V.L., Midei M.G., Malinin A.I., et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the INTERACTION study. Arch Intern Med 164 (2004) 2051-2057
16. Serebruany V.L., Malinin A.I., Jerome S.D., et al. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Am Heart J 146 (2003) 713-720
17. Ruggeri Z.M. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol 31 (1994) 229-239
18. Ault K.A. Flow cytometric measurement of platelet function and reticulated platelets. Ann N Y Acad Sci 677 (1993) 293-308
19. Cox D., Smith R., Quinn M., et al. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 36 (2000) 1514-1519
20. Serebruany V.L., Malinin A.I., O'connor C.M., et al. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy). Am Heart J 146 (2003) 91-98
21. Diener H.C., Bogousslavsky J., Brass L.M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337
22. Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
23. Serebruany V.L., Oshrine B.R., Malinin A.I., et al. Lack of uniformed platelet activation in patients after ischemic stroke, and choice of antiplatelet therapy. Thromb Res 113 (2004) 197-204
24. Gencheva E., Sloan M., Leurgans S., et al. Attrition and non-compliance in secondary stroke prevention trials. Neuroepidemiology 23 (2004) 61-66
25. Serebruany V.L., Oshrine B.R., Malinin A.I., et al. Noncompliance in clinical trials (editorial). Am Heart J 150 (2005) 882-886
26. Quick A.J. Salicylates and bleeding: the aspirin tolerance test. Am J Med Sci 252 (1966) 265-269
27. Serebruany V.L. Mortality benefit in no-load clopidogrel in COMMIT: not a surprise. J Cardiovasc Pharmacol Ther 11 (2006) 99-100
28. Chew D.P., Bhatt D.L., Sapp S., et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 103 (2001) 201-206